VUS: The Three Letters That Confuse More People Than Any Genetic Test Result

A variant of uncertain significance, or VUS, is exactly what it sounds like: a difference between your DNA and the standard reference genome that scientists have found, but haven't yet gathered enough evidence to confidently call either harmful or harmless. It sits in the middle of a five-tier classification system labs use for every variant they report: benign, likely benign, VUS, likely pathogenic, and pathogenic. A VUS isn't a diagnosis, and it isn't a clean bill of health either — it's an honest "we don't know yet," and the discomfort people feel reading that on a lab report is completely understandable.

Why VUS Results Are So Common

Every person's genome contains millions of small differences from the reference sequence used to build genetic databases. The vast majority are harmless — normal human variation, no different functionally than having brown eyes instead of blue. Labs classify a variant as benign or pathogenic based on an accumulated body of evidence: how often it shows up in healthy populations, whether it segregates with disease in affected families, what it does to protein function in lab studies, and what computational models predict about its impact. For well-studied genes and well-studied populations, that evidence pile is often large enough to classify confidently. For rare variants, or variants in less-studied genes, or found in people from populations underrepresented in reference databases, that evidence pile can be thin — and thin evidence means uncertain classification, not because your DNA is unusual, but because the reference data hasn't caught up.

The Equity Problem Hiding Inside VUS Rates

This is the part of the VUS conversation that gets skipped most often: genetic reference databases have historically skewed heavily toward people of European ancestry, which means variants common in other populations are, on average, less studied and more likely to be classified as uncertain rather than confidently benign or pathogenic — not because the underlying biology is actually more ambiguous, but because there's simply been less research on those populations. Large cohort studies analyzing VUS reclassification patterns have specifically called out the need for greater diversity in genomic reference databases as a direct fix for this imbalance. If you're from a population that's underrepresented in genomics research, you may be statistically more likely to receive a VUS result than someone with a genuinely comparable variant from a well-studied population — worth knowing so a VUS result doesn't feel like your genome is somehow more mysterious than anyone else's.

What Actually Happens to a VUS Over Time

VUS classifications aren't permanent. As more people get tested, more families are studied, and more functional lab research accumulates, labs periodically revisit VUS calls and reclassify them — usually toward benign, since most VUS turn out to be harmless once enough evidence accumulates, but sometimes toward pathogenic. One large cohort study tracking over a million individuals found VUS reclassified to benign or likely benign after an average of roughly 31 months, and reclassified to pathogenic or likely pathogenic somewhat faster, after an average of about 22 months. Other studies looking specifically at cancer genetics settings found meaningfully lower — but still real — reclassification rates over a comparable follow-up window, with a portion of those reclassifications directly changing a patient's clinical management.

What To Actually Do With a VUS Result

• Don't make major medical decisions based on a VUS alone. Professional genetics guidelines are explicit that VUS results should not, by themselves, change clinical management — no preventive surgery, no major treatment change, based on an uncertain result.
• Don't test other family members for a VUS specifically. Since it isn't actionable yet, cascading it through the family doesn't currently add value, and can add unnecessary anxiety.
• Ask your lab or provider about their reclassification and re-contact policy. Some labs proactively notify you if a variant is reclassified; others don't, and it's worth knowing which applies to you so you're not relying on remembering to check back yourself.
• Keep your raw data. If your VUS came from a targeted panel rather than whole genome sequencing, and it's later reclassified as significant, having your complete raw genomic data on hand makes any follow-up analysis faster and avoids paying for an entirely new test.

Why Whole Genome Data Handles This Better Long-Term

This is one of the strongest practical arguments for whole genome sequencing over a narrower panel: because WGS captures your complete genomic data rather than just the specific regions a panel was designed to look at, any variant that gets reclassified in the future — whether from VUS to pathogenic, or from VUS to benign — can potentially be identified by reanalyzing data you already have, without a new sample or a new test. As reference databases grow and diversify, and as classification tools improve, that raw data becomes more valuable over time rather than less.

For more on how raw sequencing data is structured, see our FASTQ, BAM, and VCF explainer, and our guide to analyzing your raw genome data. If a VUS came up in the context of family planning, our advanced family planning guide covers how uncertain results factor into reproductive decisions.